Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

NEXT STORY
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
PREV STORY
MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Athersys and Healios Extend by One Month the Period to Complete Collaboration Expansion Agreements

author_avatar
NASDAQ Market News

The global microfluidics market is projected to reach USD 58.8 billion by 2026 from USD 20.7 billion in 2021, growing at a CAGR of 23.2%

author_avatar
NASDAQ Market News

The Alliance for Regenerative Medicine Releases Complete Agenda for Sixth Annual Cell & Gene Therapy Investor Day

WASHINGTON, DC, March 28, 2018 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM) ...

author_avatar
NASDAQ Market News